Brokerages expect KemPharm, Inc. (NASDAQ:KMPH) to announce ($0.70) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for KemPharm’s earnings, with the highest EPS estimate coming in at ($0.68) and the lowest estimate coming in at ($0.71). KemPharm posted earnings of ($0.68) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 2.9%. The business is scheduled to issue its next earnings results on Thursday, March 8th.
According to Zacks, analysts expect that KemPharm will report full-year earnings of ($2.67) per share for the current fiscal year, with EPS estimates ranging from ($2.70) to ($2.64). For the next fiscal year, analysts forecast that the company will report earnings of ($2.60) per share, with EPS estimates ranging from ($2.65) to ($2.54). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow KemPharm.
Several equities analysts have issued reports on the stock. Zacks Investment Research downgraded shares of KemPharm from a “buy” rating to a “hold” rating in a report on Thursday, November 16th. ValuEngine raised shares of KemPharm from a “strong sell” rating to a “sell” rating in a report on Monday, October 23rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $7.00 price objective on shares of KemPharm in a report on Monday, September 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. KemPharm currently has an average rating of “Buy” and an average target price of $8.05.
In related news, EVP Daniel L. Cohen acquired 7,500 shares of the firm’s stock in a transaction on Monday, November 27th. The shares were acquired at an average cost of $3.79 per share, with a total value of $28,425.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Delaware Street Capital Master acquired 325,888 shares of the firm’s stock in a transaction on Thursday, September 14th. The shares were bought at an average cost of $3.27 per share, for a total transaction of $1,065,653.76. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 333,688 shares of company stock worth $1,095,213. Insiders own 25.40% of the company’s stock.
Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its stake in shares of KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 3,414 shares in the last quarter. C WorldWide Group Holding A S lifted its stake in shares of KemPharm by 14.1% in the third quarter. C WorldWide Group Holding A S now owns 435,528 shares of the specialty pharmaceutical company’s stock worth $1,611,000 after buying an additional 53,829 shares in the last quarter. Finally, Alyeska Investment Group L.P. lifted its stake in shares of KemPharm by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock worth $3,672,000 after buying an additional 17,721 shares in the last quarter. 36.04% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/11/analysts-expect-kempharm-inc-kmph-to-announce-0-70-earnings-per-share.html.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.